Hospices Civils De Lyon

The anesthesiology‑reanimation department is exploring new therapeutic approaches for heart attacks, with a focus on preserving cardiac function and reducing complications after an acute myocardial infarction.

• Assessing the effect of a single‑dose antibody therapy on heart muscle recovery after STEMI
• Comparing surgical antibiotic strategies to lower infection risk in cardiovascular procedures

Research conducted at Hospices Civils De Lyon aims to improve outcomes for patients experiencing severe cardiac events.

Studies are evaluating long‑term safety of enzyme replacement for a rare genetic disorder that affects both physical and cognitive development, seeking to enhance quality of life for affected children.

• Monitoring safety of intrathecal and intravenous enzyme therapies in patients with Hunter syndrome
• Collecting cognitive outcome data to guide future treatment guidelines

The work at Hospices Civils De Lyon supports families dealing with inherited metabolic conditions.

Clinical investigations target liver cancer that cannot be removed surgically, testing the addition of a novel autophagy inhibitor to standard immunotherapy to improve tumor control.

• Evaluating combined therapy with an autophagy inhibitor and checkpoint inhibitors
• Measuring progression‑free survival in patients with unresectable hepatocellular carcinoma

Findings from Hospices Civils De Lyon may expand treatment options for advanced liver disease.

Research is focused on anemia linked to chronic kidney disease in pediatric populations, investigating a new oral agent that stimulates red blood cell production to reduce the need for transfusions.

• Testing efficacy of a novel oral therapy for anemia in children with CKD
• Assessing safety and hematologic response over a six‑month period

The trial at Hospices Civils De Lyon seeks to improve management of kidney‑related anemia in young patients.

Advanced ovarian, fallopian‑tube and peritoneal cancers are being studied through a strategy that combines chemotherapy with targeted maintenance therapy, aiming to extend the time patients remain disease‑free after surgery.

• Comparing chemotherapy plus bevacizumab followed by maintenance versus chemotherapy alone
• Analyzing progression‑free survival at two years post‑surgery

The initiative at Hospices Civils De Lyon could set new standards for frontline treatment of gynecologic malignancies.

A trial is examining a step‑down dosing protocol for a biologic agent used in chronic eczema, aiming to maintain disease control while reducing medication exposure for adolescents and adults.

• Comparing reduced‑frequency dosing to standard maintenance therapy
• Evaluating long‑term skin severity scores over one year

Conducted at Hospices Civils De Lyon, the study addresses the balance between efficacy and safety in atopic dermatitis management.

Observational research on a recent orthopoxvirus infection gathers clinical outcomes from patients receiving antiviral therapy versus supportive care, helping to clarify optimal management strategies.

• Documenting recovery timelines in treated versus untreated mpox cases
• Assessing safety of antiviral agents in diverse patient groups

Insights from Hospices Civils De Lyon will inform public health responses to emerging viral threats.

A broad study on surgical antibiotic prophylaxis compares two commonly used drugs to determine which better prevents postoperative infections across multiple surgical specialties.

• Measuring infection rates 30 days after surgery
• Analyzing safety profiles of the two antibiotic options

This investigation at Hospices Civils De Lyon supports evidence‑based guidelines for peri‑operative care.